SIROCO SIGNED
Sparing gene therapy for Inherited ROd COne dystrophies
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SIROCO project word cloud
Explore the words cloud of the SIROCO project. It provides you a very rough idea of what is the project "SIROCO" about.
Project "SIROCO" data sheet
The following table provides information about the project.
| Coordinator |
SPARINGVISION
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 3˙529˙593 € |
| EC max contribution | 2˙470˙715 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-08-01 to 2021-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SPARINGVISION | FR (PARIS) | coordinator | 2˙470˙715.00 |
Map
Project objective
Many believe that corrective ophthalmology gene therapy is the future for rare diseases such as retinitis pigmentosa (RP), a rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors. This degenerative disease causes blindness to young people and adults. But with this kind of therapy only treating 1 out of 65 mutations of the pathology, it means a small group of patents can be targeted. So, what do the remaining 2 million people have as on option? SparingVision have developed an innovative treatment that can stop the evolution of this blindness and we call it RdCVF. The first vision saving treatment of its kind. What makes it different is that in 2004, J Sahel and T Leveillard identified that in RP, the main factor that leads to blindness is a loss of RdCVF with is a neurotrophic factor for the cones (photoreceptor). This means that by a single injection under the retina SparingVision’ product can treat all the genetic forms of RP, potentially treat patients with dry AMD, and provide patients with long lasting efficacy. In SparingVision’ proof of concept the product was injected to mice models provided almost immediate protection and repair to the cones and the evolution to blindness is stopped. Behind this product is a very strong team, a world renamed scientific advisory board. The product development has been secured with strong IP, exclusive licenses agreements and pursue R&D with research collaboration agreements and raised money. So, tomorrow with the help of SME INSTRUMENT supporting the project SIROCO, SparingVision will be able to finalize the next steps of the clinical validation of an unique therapeutic approach and make the product finally accessible and being the solution to stop unnecessary blindness and other degenerative conditions.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIROCO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SIROCO" are provided by the European Opendata Portal: CORDIS opendata.